TREC@TAMU Cancer Prevention Registry and Repository
Texas Regional Excellence in Cancer (TREC) @Texas A&M University Cancer Prevention Registry and Repository
This study collects health and genetic information to implement cancer prevention and treatment strategies.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This research will explore how genetics, diet, exercise, and jobs influence the risk of developing cancers that can be treated early. The goal is to find out if this knowledge can help doctors and health insurers improve their methods for preventing cancers that cannot be treated.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Kenneth S Ramos, MD
- Telefonnummer: 7136777740
- E-post: kramos@tamu.edu
Studer Kontakt Backup
- Navn: Rick Silva, PhD
- Telefonnummer: (713) 677-7422
- E-post: ricksilva@tamu.edu
Studiesteder
-
-
Texas
-
Bryan, Texas, Forente stater, 77802
- Rekruttering
- Texas A&M Family Care
-
Hovedetterforsker:
- Kenneth S Ramos, MD, PhD
-
Underetterforsker:
- Rick Silva, PhD
-
Underetterforsker:
- Fen Wang, PhD
-
Underetterforsker:
- Marcia Ory, PhD
-
Ta kontakt med:
- De Lona A Bacote, MS
- Telefonnummer: 7136777735
- E-post: dabacote@tamu.edu
-
Ta kontakt med:
- Gabriel Neal, MD
- Telefonnummer: 9794360399
- E-post: gneal@tamu.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
TREC@TAMU Registry will recruit as many participants as possible. The estimated enrollment in five years is expected to be 2500, but investigators will not limit recruitment if that number is exceeded.
Beskrivelse
Inclusion Criteria:
- 18 years of age and older, and,
- People participating in the Cancer Prevention and Research Institute of Texas (CPRIT) A coordinated cancer screening research program in Bryan and Navasota Family Medicine Clinics and,
- People with COPD, liver disease, cervical intraepithelial neoplasia (CIN) lesions, having had a colonoscopy or a low dose computed tomography (LDCT) lung scan or cervical exam in the last 12 months or scheduled for one, and,
- Able to give and comprehend the consent process, and,
- Able to consent to donate blood and urine samples, genetic material through buccal swabs for future research, and,
- Able to understand that their specimens, health record, and changes in health status will be followed for a five-year period and shared in deidentified form with the research community, and,
- All sexes and gender identities.
Exclusion Criteria:
- Declines to participate or interact with staff/share their medical status.
- A diagnosis of Alzheimer's disease or related dementias in a medical record indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning Individuals who are unable or unwilling to provide consent will be excluded
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: OTHER
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency and nature of ADRs on the Naranjo Scale Questionnaire
Tidsramme: 5 years
|
Measure the frequency and nature of adverse drug reactions by obtaining a complete medical history and physical examination and validating the patient's current concomitant medication list during the office visit. Patient medical information would be input into the ActX platform, which functions as a computable EHR medical record analysis, evaluation of polypharmacy status, and monitoring of ADRs using the Naranjo Scale will be conducted for the duration of the study. |
5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Self-reported Health status and any significant changes
Tidsramme: 5 years
|
The EQ-5D-5L survey, designed to collect data on health status and significant changes, will be administered to every patient in the registry at each clinic visit and at least every six months for five years after enrollment. The EQ-5D-5L consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension features five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Patients indicate their health state by ticking the box next to the most appropriate statement for each dimension. This choice generates a one-digit number representing the selected level for that dimension. The numbers from the five dimensions can be combined into a five-digit number that characterizes the patient's health state. |
5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY2024-0008
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .